@inbook{dd8f4db2eb3d4ab7a61e2e5518704681,
title = "CHAPTER 16: Pyridinobenzodiazepines (PDDs) as Sequence-selective DNA Mono-alkylating Antibody-Drug Conjugate (ADC) Payloads",
abstract = "Since the discovery of anthramycin in the early 1960s1 and its subsequent clinical evaluation,2 a range of synthetic pyrrolobenzodiazepines (PBDs)3 have been developed by various groups. For example, the C8-linked PBD dimer tesirine (discussed in Chapter 14) has been incorporated into a number of ADCs currently in clinical development,4 and synthetic mono-alkylating 'pseudodimers' [e.g. the indolinobenzodiazepines (IGNs)5 discussed in Chapter 15] and other types of DNA cross-linkers (e.g., the isoquinolidinobenzodiazepines6) have also been incorporated into pre-clinical and clinical ADC candidates7 (Figure 16.1). However, ADC payload molecules of this type are promiscuous in only having a limited ability to target specific sequences of DNA.",
author = "Nicolas Veillard and Francesco Cascio and Jackson, {Paul J.M.} and Thurston, {David E.}",
year = "2019",
month = jan,
day = "1",
doi = "10.1039/9781788012898-00349",
language = "English",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
number = "71",
pages = "349--363",
editor = "Thurston, {David E.} and Jackson, {Paul J. M.}",
booktitle = "Therapies for Retinal Degeneration",
address = "United Kingdom",
edition = "71",
}